target directory

her2 positive metastatic breast cancer clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT02073916

Source recordAI-normalized

Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients

This clinical trial evaluated the safety and tolerability of a combination therapy involving trastuzumab emtansine (T-DM1), Lapatinib, and Abraxane in patients with metastatic HER2-positive breast cancer. The study was conducted by The Methodist Hospital Research Institute and completed in December 2018 with 24 participants.

AI analysis

Indication: Metastatic Breast Cancer

Modality: small molecule

Target: HER2-positive metastatic breast cancer

Sponsor: Jenny C. Chang, MD

Source URL: ClinicalTrials.gov

Source updated: Apr 16, 2019

Ingested: Jun 05, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: HER2-positive metastatic breast cancer

View original source fields

Condition raw: Metastatic Breast Cancer

Condition normalized: Metastatic Breast Cancer

Modality raw: small molecule

Modality normalized: small molecule

Target raw: T-DM1, Lapatinib, Abraxane

Target normalized: HER2-positive metastatic breast cancer

Open report

NCT01835236

Source recordAI-normalized

A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer

This clinical trial evaluates a novel treatment strategy for HER2-positive metastatic breast cancer, comparing a chemotherapy-free regimen of trastuzumab and pertuzumab followed by T-DM1 against a chemotherapy-inclusive regimen. The study aims to determine if the new strategy offers similar or improved efficacy and tolerability compared to standard treatments.

AI analysis

Indication: Metastatic Breast Cancer

Modality: monoclonal antibody

Target: HER2-positive Metastatic Breast Cancer

Sponsor: Swiss Cancer Institute

Source URL: ClinicalTrials.gov

Source updated: Mar 30, 2021

Ingested: Jun 05, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: HER2-positive Metastatic Breast Cancer

View original source fields

Condition raw: Metastatic Breast Cancer

NCT06663787

Source recordAI-normalized

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment

This clinical trial aims to evaluate the status of circulating tumor DNA (ctDNA) in patients with HER2-positive metastatic breast cancer who have achieved a durable response to anti-HER2 treatment. The study utilizes the Signatera™ ctDNA assay to assess minimal residual disease (MRD) and explore potential new therapeutic strategies, including the possibility of de-escalating treatment in ctDNA-negative patients.

AI analysis

Indication: Breast Cancer, Metastatic

Modality: monoclonal antibody

Target: HER2-positive metastatic breast cancer

Sponsor: Nagoya City University

Source URL: ClinicalTrials.gov

Source updated: May 13, 2026

Ingested: May 23, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: HER2-positive metastatic breast cancer

View original source fields

Condition raw: Breast Cancer, Metastatic, HER2 + Breast Cancer